Teva chief commits to a broad offering
Teva will continue to offer a comprehensive portfolio of both standard and complex generics, as well as biosimilars, as it seeks to defend its position as the world’s leading generics supplier, according to Kåre Schultz, who took charge as the Israeli group’s chief executive officer in November last year.
You may also be interested in...
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.